文献速递消化道肿瘤与早癌消化内镜

内镜背景黏膜重铺预防浅表食管鳞癌治愈性内镜黏膜下剥离术后异时性复发:随机先导研究及5年随访(附视频)

Endoscopic background mucosal resurfacing to prevent metachronous recurrence of superficial esophageal squamous cell cancer after curative endoscopic submucosal dissection: randomized pilot study with 5-year follow-up (with video).
PubMed 文献 · Gastrointest Endosc · 2024-11-08

该随机先导研究纳入112例筛查患者中的30例,将治愈性内镜黏膜下剥离术后背景黏膜呈斑点状碘染表现者按1:1随机分为内镜射频消融背景黏膜重铺组(n=15)与单纯内镜监测组(n=15)。5年随访中,背景黏膜重铺组异时性复发率为0%,对照组为53%(P=.001),需治疗人数为1.9;背景黏膜重铺组1例发生射频消融后狭窄,经3次内镜扩张后缓解。

要点

  • 背景黏膜重铺组5年异时性复发率0%,对照组53%,P=.001,需治疗人数1.9。
  • 背景黏膜重铺平均操作时间30.7分钟(范围25-40分钟)。
  • 1例射频消融后狭窄,经3次内镜扩张后缓解;碘染斑点状表现均逆转为少量碘不染区并持续至少5年。

核心结论

  • 在治愈性内镜黏膜下剥离术后背景黏膜存在多个小碘不染区的患者中,球囊型射频消融行背景黏膜重铺在5年随访中是一种有前景且安全的预防异时性复发的方法。

研究设计与样本

  • 随机对照先导研究,纳入治愈性内镜黏膜下剥离术后碘染背景黏膜呈斑点状表现的患者,按1:1随机分为内镜射频消融背景黏膜重铺组(n=15)与单纯内镜监测组(n=15)。
  • 筛查112例,随机30例;背景黏膜重铺于内镜黏膜下剥离术后2至3个月用球囊装置对全食管黏膜行环周消融。
  • 主要结局为5年随访期间鳞状上皮肿瘤异时性复发,次要结局为主要不良事件。

主要发现

  • 背景黏膜重铺组异时性复发率0% vs 对照组53%(P=.001),需治疗人数1.9。
  • 背景黏膜重铺平均操作时间30.7分钟(范围25-40分钟)。
  • 1例发生射频消融后狭窄,经3次内镜扩张后缓解。
  • 消融组所有患者碘染斑点状表现逆转为仅少量碘不染区,并持续至少5年。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Metachronous recurrence frequently develops in patients with superficial esophageal squamous cell carcinomas (ESCCs) after curative endoscopic submucosal dissection (ESD), especially in those with multiple (>10) small Lugol-voiding lesions (LVLs) over the endoscopic background mucosa (ie, speckled pattern). We conducted a randomized controlled trial to investigate whether endoscopic radiofrequency ablation (RFA) for endoscopic background mucosal resurfacing (EBMR) can decrease the rate of metachronous neoplasia. METHODS: Patients who received curative ESD and whose Lugol staining showed a speckled pattern over the background mucosa were randomly assigned in a 1:1 ratio to receive either RFA (EBMR group) or endoscopic surveillance alone (control group). EBMR with RFA was performed with a balloon device for circumferential ablation of the total esophageal mucosa 2 to 3 months after ESD. The primary outcome was the metachronous recurrence of squamous neoplasia during a 5-year follow-up period. Secondary outcomes were major adverse events. RESULTS: Of 112 patients screened, 30 were randomized to receive EBMR (n = 15) or surveillance (n = 15). The mean procedure time of EBMR was 30.7 minutes (range, 25-40). One patient developed post-RFA stenosis, which resolved after 3 sessions of endoscopic dilation. EBMR reduced the risk of metachronous recurrence (0% in the EBMR group vs 53% in the control group, P = .001), with a number needed to treat of 1.9. Reversal of the Lugol-staining speckled pattern to only a few LVLs occurred in all patients and persisted for at least 5 years in the ablation group. CONCLUSIONS: In this randomized trial of patients with multiple small LVLs over the endoscopic background after curative ESD, EBMR with balloon-type RFA is a promising and safe procedure for preventing metachronous recurrence over 5 years of follow-up. (Clinical trial registration number: NCT03183115.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Wang WL, Tsai YN, Hsu MH, et al. Endoscopic background mucosal resurfacing to prevent metachronous recurrence of superficial esophageal squamous cell cancer after curative endoscopic submucosal dissection: randomized pilot study with 5-year follow-up (with video). Gastrointest Endosc. 2024. PMID: 39521094. doi:10.1016/j.gie.2024.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。